Sensus Healthcare 2025 Q3 Earnings Sharp Net Loss of 185.7% Drives Volatile Share Price

Sensus Healthcare (SRTS) reported a significant earnings shortfall for Q3 2025, marked by a net loss of $0.06 per share and a 22.1% revenue decline. The company provided no financial guidance, citing risks including regulatory challenges and competitive pressures.

Revenue

Product revenue accounted for $5.36 million, while service revenue contributed $1.52 million, totaling $6.88 million. This represents a 22.1% year-over-year drop from $8.84 million, driven by declining sales in core segments.

Earnings/Net Income

Sensus Healthcare swung to a loss of $0.06 per share in Q3 2025, compared to a $0.07 per share profit in Q3 2024, reflecting a 185.7% negative change. The company reported a net loss of $943,000, a stark deterioration from its $1.22 million net income a year earlier. The earnings downturn highlights operational challenges and margin compression.

Price Action

The stock price of Sensus Healthcare dropped 4.70% during the latest trading day, despite surging 26.70% during the most recent full trading week and 38.51% month-to-date.

Post-Earnings Price Action Review

Despite the earnings miss, the stock exhibited a volatile reaction, with a sharp intraweek rally contrasting the post-earnings decline. The 38.51% monthly gain suggests investor optimism amid uncertainty, though the 4.70% daily drop indicates short-term skepticism. The mixed signals underscore the market’s cautious stance on the company’s near-term prospects.

CEO Commentary

Joe Sardano, Chairman and CEO, emphasized Eric Sachetta’s leadership in driving growth and aligning with the company’s mission. He highlighted Sachetta’s strategic and operational expertise as pivotal to advancing SRT technology and expanding global clinical impact.

Guidance

The company’s forward-looking statements caution against inflationary pressures, reimbursement risks, and regulatory hurdles. No specific revenue or EPS targets were provided, leaving uncertainty about future performance.

Additional News

On November 11, 2025, Sensus Healthcare’s President, Michael Sardano, purchased 2,000 shares at $4.26, totaling $8,523. The transaction, disclosed via Form 4/A, reflects insider confidence amid the company’s recent earnings struggles. Sardano’s indirect holdings now stand at 118,839 shares. The purchase occurred days before the Q3 earnings report, signaling potential strategic optimism from leadership.